<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099761</url>
  </required_header>
  <id_info>
    <org_study_id>A031-03</org_study_id>
    <nct_id>NCT01099761</nct_id>
  </id_info>
  <brief_title>Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ACE-031 is safe and well-tolerated in boys with
      Duchenne Muscular Dystrophy (DMD) and to select the optimal doses of ACE-031 in terms of
      safety and pharmacodynamic (PD) activity for designing future studies. [Note: This study was
      terminated based on safety data]
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ACE-031, a soluble form of the human activin receptor type IIB, was administered once every 2
      to 4 weeks by subcutaneous (SC) injection to boys with DMD. Dose levels and regimens for this
      multiple-dose study were based on data from the initial clinical studies in healthy subjects
      in which doses of 0.02 to 3 mg/kg SC were evaluated. A total of 24 subjects were enrolled
      into the study; 18 received ACE-031 and 6 placebo. All subjects were treated for a period of
      12 weeks.The pharmacodynamic effects of ACE-031 treatment were assessed by a battery of motor
      function test that included the 6-Minute Walk Test, the 10-Minute Walk/Run Test, the 4-Stair
      Climb Test and the Gower Maneuver (GW). Muscle strength was assessed by hand-held myometry
      and fixed system testing. Body composition (i.e., spine BMD, lean mass, and fat mass) was
      assessed by whole body and lumbar spine DXA scans. Pulmonary function was assessed by forced
      vital capacity (FVC), maximal inspiratory pressure (MIP) and maximal expiratory pressure
      (MEP). ACE-031 safety was evaluated through observation of the incidence and severity of
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on preliminary safety data.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Reactions.</measure>
    <time_frame>From treatment initiation to End-of-Study Visit, approximately 24 weeks later</time_frame>
    <description>Number of subjects in each cohort with a treatment-emergent adverse event considered at least possibly related to study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Clinical Laboratory Adverse Reactions.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
    <description>Number of subjects in each cohort with treatment-emergent adverse laboratory values judged to be at least possibly related to study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lean Body Mass by DXA Scan.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Lumbar Spine Bone Mineral Density by DXA Scan.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Muscle Strength Score by Hand-held Myometry.</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
    <description>Manual Muscle Testing (MMT) is a procedure to measure the function and strength of individual muscles and muscle groups. Hand-held myometry, using a device known as a dynamometer, is one method used for MMT. The dynamometer is held against the patient's limb by the examiner and the patient is asked to resist the force applied by the examiner. The dynamometer measures the force applied by the patient, providing a quantitative and objective assessment of strength of the particular muscle or muscle group. The effectiveness of a therapeutic intervention on muscle strength, as measured by hand-held myometry, can be assessed by comparing post-treatment to pre-treatment (baseline) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Distance Traveled in 6 Minutes (Standardized 6-Minute-Walk Test).</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
    <description>Change in distance traveled in 6 minutes (standardized 6-Minute-Walk Test); stratified by baseline age (&lt;10 years vs. &gt;=10 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Travel 10 Meters (Standardized 10-Meter-Walk/Run Test).</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function Tests (FVC)</measure>
    <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
    <description>Forced Vital Capacity (FVC); 1 of 3 separate tests employed to assess pulmonary function in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function Test (MIP)</measure>
    <time_frame>Baseline to End-of-Study Visit. approximately 24 weeks</time_frame>
    <description>Maximum Inspiratory Pressure (MIP); 2 of 3 separate tests employed to assess pulmonary function in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function Test (MEP)</measure>
    <time_frame>Baseline to End-of-Stuidy Visit, approximately 24 weeks</time_frame>
    <description>Maximum Expiratory Pressure (MEP); 3 of 3 separate tests employed to assess pulmonary function in this study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>ACE-031 0.5 mg/kg q4wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-031 1.0 mg/kg q2wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-031 0.5 mg/kg q4wk</intervention_name>
    <description>ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
    <arm_group_label>ACE-031 0.5 mg/kg q4wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACE-031 1.0 mg/kg q2wk</intervention_name>
    <description>ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
    <arm_group_label>ACE-031 1.0 mg/kg q2wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of DMD confirmed

          -  Ambulant

          -  Corticosteroid therapy for at least one year prior to study day 1 and on a stable dose
             and schedule for at least 6 months prior to study day 1

          -  Evidence of muscle weakness by clinical assessment

        Exclusion Criteria:

          -  Any previous treatment with another investigational product within 6 months prior to
             study day 1

          -  Any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic,
             metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or
             other major disease that is not related to DMD

          -  Inability to perform a whole body dual x-ray absorptiometry (DXA) scan
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>April 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2010</study_first_posted>
  <results_first_submitted>May 10, 2016</results_first_submitted>
  <results_first_submitted_qc>August 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 14, 2016</results_first_posted>
  <disposition_first_submitted>January 24, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 4, 2013</disposition_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Abstract summarizing trial data has been published online in Muscle &amp; Nerve 23-Dec-2016 https://www.ncbi.nlm.nih.gov/pubmed/27462804 The Sponor currently has no plans to make IPD available for a number of reasons; (i) the study was terminated by the Sponsor prematurely based upon concerns for potential adverse drug reactions following long-term use, which were identified in chronic toxicity studies in animals, (ii) the study population was one with a rare disease, in a groups of subjects with a relatively narrow age range, across a small number of study sites. The Sponsor believes that these factors, taken together, make patient anonymity a significant challenge.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ACE-031 0.5 mg/kg q4wk</title>
          <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>ACE-031 1.0 mg/kg q2wk</title>
          <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>ACE-031 ACE-03 2.5 mg/kg q4wk</title>
          <description>ACE-031 2.5 mg/kg q4wk: ACE-031 2.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0">Study terminated prior to enrolling cohort 3</participants>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACE-031 0.5 mg/kg q4wk</title>
          <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>ACE-031 1.0 mg/kg q2wk</title>
          <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>ACE-031 ACE-03 2.5 mg/kg q4wk</title>
          <description>ACE-031 2.5 mg/kg q4wk: ACE-031 2.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Able to ambulate 10 meters in &lt; 12 seconds</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Reactions.</title>
        <description>Number of subjects in each cohort with a treatment-emergent adverse event considered at least possibly related to study drug</description>
        <time_frame>From treatment initiation to End-of-Study Visit, approximately 24 weeks later</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Reactions.</title>
          <description>Number of subjects in each cohort with a treatment-emergent adverse event considered at least possibly related to study drug</description>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Clinical Laboratory Adverse Reactions.</title>
        <description>Number of subjects in each cohort with treatment-emergent adverse laboratory values judged to be at least possibly related to study drug</description>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Laboratory Adverse Reactions.</title>
          <description>Number of subjects in each cohort with treatment-emergent adverse laboratory values judged to be at least possibly related to study drug</description>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Lean Body Mass by DXA Scan.</title>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Lean Body Mass by DXA Scan.</title>
          <units>percentage change in lean body mass</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.3"/>
                    <measurement group_id="O2" value="4.1" spread="1.5"/>
                    <measurement group_id="O3" value="2.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.435</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Lumbar Spine Bone Mineral Density by DXA Scan.</title>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lumbar Spine Bone Mineral Density by DXA Scan.</title>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.8"/>
                    <measurement group_id="O2" value="4.4" spread="1.5"/>
                    <measurement group_id="O3" value="0.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Muscle Strength Score by Hand-held Myometry.</title>
        <description>Manual Muscle Testing (MMT) is a procedure to measure the function and strength of individual muscles and muscle groups. Hand-held myometry, using a device known as a dynamometer, is one method used for MMT. The dynamometer is held against the patient's limb by the examiner and the patient is asked to resist the force applied by the examiner. The dynamometer measures the force applied by the patient, providing a quantitative and objective assessment of strength of the particular muscle or muscle group. The effectiveness of a therapeutic intervention on muscle strength, as measured by hand-held myometry, can be assessed by comparing post-treatment to pre-treatment (baseline) measurements.</description>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Muscle Strength Score by Hand-held Myometry.</title>
          <description>Manual Muscle Testing (MMT) is a procedure to measure the function and strength of individual muscles and muscle groups. Hand-held myometry, using a device known as a dynamometer, is one method used for MMT. The dynamometer is held against the patient's limb by the examiner and the patient is asked to resist the force applied by the examiner. The dynamometer measures the force applied by the patient, providing a quantitative and objective assessment of strength of the particular muscle or muscle group. The effectiveness of a therapeutic intervention on muscle strength, as measured by hand-held myometry, can be assessed by comparing post-treatment to pre-treatment (baseline) measurements.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elbow extension (kg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.2"/>
                    <measurement group_id="O2" value="0.1" spread="2.3"/>
                    <measurement group_id="O3" value="-0.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elbow flexion (kg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="3.4"/>
                    <measurement group_id="O2" value="-0.7" spread="2.6"/>
                    <measurement group_id="O3" value="0.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Knee extension (kg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="4.4"/>
                    <measurement group_id="O2" value="-3.3" spread="4.4"/>
                    <measurement group_id="O3" value="-3.7" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Knee flexion (kg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="3.1"/>
                    <measurement group_id="O2" value="-1.9" spread="4.1"/>
                    <measurement group_id="O3" value="-1.2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Distance Traveled in 6 Minutes (Standardized 6-Minute-Walk Test).</title>
        <description>Change in distance traveled in 6 minutes (standardized 6-Minute-Walk Test); stratified by baseline age (&lt;10 years vs. &gt;=10 years)</description>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distance Traveled in 6 Minutes (Standardized 6-Minute-Walk Test).</title>
          <description>Change in distance traveled in 6 minutes (standardized 6-Minute-Walk Test); stratified by baseline age (&lt;10 years vs. &gt;=10 years)</description>
          <units>change (m) in 6MWT from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;10 years of age at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="61.5"/>
                    <measurement group_id="O2" value="2.5" spread="35.6"/>
                    <measurement group_id="O3" value="5.2" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=10 years of age at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="37.6"/>
                    <measurement group_id="O2" value="-3.2" spread="35.5"/>
                    <measurement group_id="O3" value="-47.6" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time to Travel 10 Meters (Standardized 10-Meter-Walk/Run Test).</title>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time to Travel 10 Meters (Standardized 10-Meter-Walk/Run Test).</title>
          <units>Change (sec) in 10MWT from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                    <measurement group_id="O2" value="0.7" spread="0.9"/>
                    <measurement group_id="O3" value="1.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Function Tests (FVC)</title>
        <description>Forced Vital Capacity (FVC); 1 of 3 separate tests employed to assess pulmonary function in this study</description>
        <time_frame>Baseline to End-of-Study Visit, approximately 24 weeks later.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Function Tests (FVC)</title>
          <description>Forced Vital Capacity (FVC); 1 of 3 separate tests employed to assess pulmonary function in this study</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                    <measurement group_id="O3" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Function Test (MIP)</title>
        <description>Maximum Inspiratory Pressure (MIP); 2 of 3 separate tests employed to assess pulmonary function in this study</description>
        <time_frame>Baseline to End-of-Study Visit. approximately 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Function Test (MIP)</title>
          <description>Maximum Inspiratory Pressure (MIP); 2 of 3 separate tests employed to assess pulmonary function in this study</description>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="17.2"/>
                    <measurement group_id="O2" value="8.7" spread="7.6"/>
                    <measurement group_id="O3" value="8.8" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Function Test (MEP)</title>
        <description>Maximum Expiratory Pressure (MEP); 3 of 3 separate tests employed to assess pulmonary function in this study</description>
        <time_frame>Baseline to End-of-Stuidy Visit, approximately 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACE-031 0.5 mg/kg q4wk</title>
            <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ACE-031 1.0 mg/kg q2wk</title>
            <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Function Test (MEP)</title>
          <description>Maximum Expiratory Pressure (MEP); 3 of 3 separate tests employed to assess pulmonary function in this study</description>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="12.5"/>
                    <measurement group_id="O2" value="0.8" spread="3.9"/>
                    <measurement group_id="O3" value="5.8" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks (12 weeks treatment period + 12 weeks follow up)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACE-031 0.5 mg/kg q4wk</title>
          <description>ACE-031 0.5 mg/kg q4wk: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>ACE-031 1.0 mg/kg q2wk</title>
          <description>ACE-031 1.0 mg/kg q2wk: ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>ACE-031 ACE-03 2.5 mg/kg q4wk</title>
          <description>ACE-031 2.5 mg/kg q4wk: ACE-031 2.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Attie</name_or_title>
      <organization>Acceleron Pharma</organization>
      <phone>617-649-9200 ext 350</phone>
      <email>kattie@xlrn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

